"Is a cure in my sight?" Multi-stakeholder perspectives on phase I choroideremia gene transfer clinical trials

Genetics in Medicine

Volumn 16, Issue 5, 2014, Pages 379-385

  Benjaminy, Shelly ^a   Macdonald, Ian ^a   Bubela, Tania ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

choroideremia; gene therapy; gene transfer; informed consent; phase I

Indexed keywords

ARTICLE; CHOROIDEREMIA; CLINICAL RESEARCH; GENE TRANSFER; HEALTH CARE PERSONNEL; HUMAN; INFORMED CONSENT; PATIENT ADVOCACY; PATIENT PARTICIPATION; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; STUDY DESIGN; VISION; CLINICAL TRIAL; GENE THERAPY; GENETICS; INFORMATION PROCESSING; MALE; PHASE 1 CLINICAL TRIAL; RISK; VISUAL ACUITY;

CHOROIDEREMIA; DATA COLLECTION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; INFORMED CONSENT; MALE; RISK; VISUAL ACUITY;

EID: 84899933131     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.148     Document Type: Article

References (40)

1. Stockdale A. Waiting for the cure: Mapping the social relations of human gene therapy research. Sociol Health Illn 1999;21:579-596.
2. Branca MA. Gene therapy: Cursed or inching towards credibility? Nat Biotechnol 2005;23:519-521.
3. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-2239.
4. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adenoassociated virus gene vector: Short-Term results of a phase I trial. Hum Gene Ther 2008;19:979-990.
5. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
6. Koenekoop RK. Successful RPE65 gene replacement and improved visual function in humans. Ophthalmic Genet 2008;29:89-91.
7. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 2009;374:1597-1605.
8. Héon E. My child has Leber congenital amaurosis: Why is he/she not eligible for gene therapy trials? J AAPOS 2009;13:533-534.
9. Wojno AP, Pierce EA, Bennett J. Seeing the light. Sci Transl Med 2013;5:175fs8.
10. MacDonald IM, Russell L, Chan CC. Choroideremia: New findings from ocular pathology and review of recent literature. Surv Ophthalmol 2009;54:401-407.
11. Benjaminy S. Ocular gene transfer communications: Developing ethical frameworks for phase I choroideremia clinical trials [dissertation]. Department of Public Health Sciences, University of Alberta: Edmonton, Alberta, 2013.
12. Kimmelman J. Gene Transfer and the Ethics of First-in-Human Research: Lost in Translation. Cambridge University Press: Cambridge, UK; 2010.
13. Appelbaum PS, Roth LH, Lidz C. The therapeutic misconception: Informed consent in psychiatric research. Int J Law Psychiatry 1982;5:319-329.
14. Horng S, Grady C. Misunderstanding in clinical research: Distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB 2003;25:11-16.
15. Henderson GE, Davis AM, King NM, et al. Uncertain benefit: Investigators' views and communications in early phase gene transfer trials. Mol Ther 2004;10:225-231.
16. Kent A, King NM, Cohen-Haguenauer O. Toward a proportionate regulatory framework for gene transfer: A patient group-led initiative. Hum Gene Ther 2011;22:126-134.
17. Illes J, Reimer JC, Kwon BK. Stem cell clinical trials for spinal cord injury: Readiness, reluctance, redefinition. Stem Cell Rev 2011;7:997-1005.
18. Wilson JM. Medicine. A history lesson for stem cells. Science 2009;324:727-728.
19. Henderson GE, Easter MM, Zimmer C, et al. Therapeutic misconception in early phase gene transfer trials. Soc Sci Med 2006;62:239-253.
20. McAllister M, Davies L, Payne K, Nicholls S, Donnai D, MacLeod R. The emotional effects of genetic diseases: Implications for clinical genetics. Am J Med Genet A 2007;143A:2651-2661.
21. Charmaz K. Constructing Grounded Theory: A Practical Guide through Qualitative Analysis. Sage Publications: Thousand Oaks, CA; 2006.
22. King NM. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics 2000;28:332-343.
23. Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci USA 2005;102:6177-6182.
24. Kwon BK, Ghag A, Dvorak MF, Tetzlaff W, Illes J. Expectations of benefit and tolerance to risk of individuals with spinal cord injury regarding potential participation in clinical trials. J Neurotrauma 2012;29:2727-2737.
25. Pentz RD, White M, Harvey RD, et al. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer 2012;118:4571-4578.
26. Miller VA, Baker JN, Leek AC, et al. Adolescent perspectives on phase I cancer research. Pediatr Blood Cancer 2013;60:873-878.
27. Sulmasy DP, Astrow AB, He MK, et al. The culture of faith and hope: Patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 2010;116:3702-3711.
28. Evans R, Kotchetkova I, Langer S. Just around the corner: Rhetorics of progress and promise in genetic research. Public Underst Sci 2009;18:43-59.
29. Kimmelman J. Ethics of cancer gene transfer clinical research. Methods Mol Biol 2009;542:423-445.
30. Miller FG, Joffe S. Phase 1 oncology trials and informed consent. J Med Ethics e-pub ahead of print 17 November, 2012. doi:10.1136/medethics-2012- 100832.
31. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA 2013;110:E517-E525.
32. Hyun I. Therapeutic hope, spiritual distress, and the problem of stem cell tourism. Cell Stem Cell 2013;12:505-507.
33. Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 2000;18:421-428.
34. Weinfurt KP, Castel LD, Li Y, et al. The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer 2003;98:166-175.
35. Kim SY, Holloway RG, Frank S, Wilson R, Kieburtz K. Trust in early phase research: Therapeutic optimism and protective pessimism. Med Health Care Philos 2008;11:393-401.
36. Kimmelman J. The ethics of human gene transfer. Nat Rev Genet 2008;9:239-244.
37. Petersen A. The ethics of expectations: Biobanks and the promise of personalised medicine. Monash Bioeth Rev 2009;28:5.1-512.
38. Innes S, Payne S. Advanced cancer patients' prognostic information preferences: A review. Palliat Med 2009;23:29-39.
39. Reimer J, Borgelt E, Illes J. In pursuit of 'informed hope' in the stem cell discourse. Am J Bioeth 2010;10:31-32.
40. Glassman RH, Sun AY. Biotechnology: Identifying advances from the hype. Nat Rev Drug Discov 2004;3:177-183.